Jennison Associates
29
83M
27
0.54
0.07
23
- Stages of investment
- Areas of investment
Summary
Jennison Associates appeared to be the Corporate Investor, which was created in 1969. The main office of represented Corporate Investor is situated in the New York. The company was established in North America in United States.
Besides them, we counted 21 critical employees of this fund in our database.
Among the most popular portfolio startups of the fund, we may highlight Avanir Pharmaceuticals, Allogene Therapeutics, Afferent Pharmaceuticals. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Medical Device, Life Science. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager.
The standard case for the fund is to invest in rounds with 8-9 partakers. Despite the Jennison Associates, startups are often financed by Domain Associates, OrbiMed, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Fidelity Management and Research Company, RA Capital Management. In the next rounds fund is usually obtained by Silicon Valley Bank, Oxford Finance LLC, HBM Healthcare Investments AG.
Comparing to the other companies, this Jennison Associates performs on 66 percentage points more the average number of lead investments. The fund is constantly included in less than 2 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top activity for fund was in 2015. The top amount of exits for fund were in 2015.
Investments analytics
Analytics
- Total investments
- 29
- Lead investments
- 0
- Exits
- 23
- Rounds per year
- 0.54
- Follow on index
- 0.07
- Investments by industry
- Biotechnology (23)
- Health Care (17)
- Therapeutics (10)
- Medical (8)
- Pharmaceutical (6) Show 14 more
- Investments by region
-
- United States (26)
- Canada (1)
- France (1)
- Peak activity year
- 2015
- Number of Unicorns
- 3
- Number of Decacorns
- 3
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 150M
- Group Appearance index
- 0.97
- Avg. company exit year
- 4
- Avg. multiplicator
- 7.87
- Strategy success index
- 0.90
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| GenSight Biologics | 23 Jul 2015 | Biotechnology, Health Care, Genetics, Medical | Early Stage Venture | 36M | Ile-de-France, Paris, France |
| Ovid Therapeutics | 11 Aug 2015 | Biotechnology, Health Care, Biopharma | Early Stage Venture | 75M | United States, New York, New York |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.